IP Library Granted Patent US 10,695,444
Granted Patent B2
US 10,695,444 · App. 16/268,902 · Granted Jun 30, 2020

Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof

Inventors: Daniel Griffith Anderson (Framingham, MA); Joseph R. Dorkin (Somerville, MA); Owen Shea Fenton (Somerville, MA); Kevin John Kauffman (Somerville, MA); Rebecca L. McClellan (Westwood, MA)
Assignee: Massachusetts Institute of Technology
A61K48/0033A61K38/1816A61K47/545C07D241/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,695,444
App. No.
16/268,902
Granted
Jun 30, 2020
Kind
B2
Abstract

Provided herein are compounds of Formula (I), and salts thereof, wherein each instance of R L is independently optionally substituted C 6 -C 40 alkenyl. Further provided are compositions comprising a compound of Formula (I) and an agent. Further provided are methods and kits using the compositions for delivering an agent to a subject or cell and for treating and/or preventing a range of diseases. Further provided are methods of preparing compounds of Formula (I) and precursors thereof.

Claims (31)

1. A composition comprising:

a compound of Formula (I):

or a salt thereof, wherein each instance of R L is independently optionally substituted C 6 -C 40 alkenyl comprising only cis double bonds; and

optionally, an excipient.

2. The composition of claim 1 , further comprising a hydrophilic polymer.

3. The composition of claim 2 , wherein the hydrophilic polymer is polyethylene glycol (PEG).

4. The composition of claim 1 , further comprising a lipid.

5. The composition of claim 4 , wherein the lipid is a triglyceride, a diglyceride, a PEGylated lipid, a phospholipid, a steroid, a substituted or unsubstituted cholesterol, an apolipoprotein, or a combination thereof.

6. The composition of claim 5 , wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, or 18-1-trans PE, or 1-stearoyl-2-oleoyl-phosphatidyethanolamine (S OPE).

7. The composition of claim 5 , wherein the PEGylated lipid is PEGylated cholesterol, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (C 14 -PEG 2000, Avanti), N-octanoyl-sphingosine-1-[succinyl(methoxy polyethylene glycol)-2000], or dimyristoylglycerol (DMG)-PEG-2K.

8. The composition of claim 5 , wherein the PEGylated lipid comprises a poly(ethylene) glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C 6 -C 20 length.

9. The composition of claim 1 , further comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and C14-PEG-2000.

10. The composition of claim 1 , further comprising at least two components selected from the group consisting of: hydrophilic polymers, triglycerides, diglycerides, PEGylated lipids, phospholipids, steroids, substituted or unsubstituted cholesterols, and apolipoproteins.

11. The composition of claim 1 , further comprising an agent.

12. The composition of claim 11 , wherein the agent is an organic molecule, inorganic molecule, nucleic acid, protein, peptide, polynucleotide, targeting agent, an isotopically labeled chemical compound, vaccine, an immunological agent, or an agent useful in bioprocessing.

13. The composition of claim 12 , wherein the agent is a polynucleotide.

14. The composition of claim 13 , wherein the polynucleotide is RNA.

15. The composition of claim 14 , wherein the RNA is messenger RNA, single-stranded RNA, double-stranded RNA, small interfering RNA, precursor messenger RNA, small hairpin RNA, microRNA, guide RNA, transfer RNA, antisense RNA, heterogeneous nuclear RNA, coding RNA, non-coding RNA, long non-coding RNA, satellite RNA, viral satellite RNA, signal recognition particle RNA, small cytoplasmic RNA, small nuclear RNA, ribosomal RNA, Piwi-interacting RNA, polyinosinic acid, ribozyme, flexizyme, small nucleolar RNA, spliced leader RNA, viral RNA, or viral satellite RNA.

16. The composition of claim 14 , wherein the RNA is messenger RNA.

17. The composition of claim 11 , wherein the polynucleotide is DNA.

18. The composition of claim 1 , wherein at least one instance of R L is a group of formula:

wherein:

x is an integer between 4 and 20, inclusive;

y is an integer between 1 and 20, inclusive;

each instance of z1 and z2 is independently 1, 2, or 3; and

each instance of R′ is or hydrogen, optionally substituted C 1-6 alkyl, halogen, substituted hydroxyl, substituted thiol, and substituted amino;

provided the group comprises no more than 40 linear carbon atoms.

19. The composition of claim 1 , wherein at least one instance of R L is:

20. The composition of claim 1 , wherein the compound of Formula (I) has a structure selected from:

21. The composition of claim 1 , wherein the compound of Formula (I) is

22. The composition of claim 21 , further comprising messenger RNA.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 4, 2022
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061883/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2019
From: ANDERSON, DANIEL GRIFFITH; DORKIN, JOSEPH R.; FENTON, OWEN SHEA; KAUFFMAN, KEVIN JOHN; MCCLELLAN, REBECCA L.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 049091/0079 →
Continuity (3)
Continuation 15186361 · Jun 17, 2016
Provisional Application 62182264 · Jun 19, 2015
Related Publication 20190240349A1 · Aug 8, 2019
Cited By (3)
US 12,239,735 US 12,390,528 US 12,648,959